Pathophysiological role of cytokines in congestive heart failure

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 15-27

  Blum, A ^a   Miller, H ^a  

^a Poriya Hospital   (Israel)

Author keywords

Atrial natriuretic factor; Dilated cardiomyopathy; Interleukin 1 ; Interleukin 2; Interleukin 6; Major histocompatibility complex; Monoclonal antibodies; Tumor necrosis factor

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; ETANERCEPT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CELLULAR IMMUNITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; HEART DILATATION; HUMAN; HUMORAL IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; AUTONOMIC NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-6; NEUROTRANSMITTER AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035123655     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.15     Document Type: Review

References (84)

1. The management of chronic heart failure
2. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition
3. Stretching cardiac myocytes stimulates protooncogene expression
4. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response
5. Heart failure with normal ejection fraction: The V-HeFT study
6. Intact systolic left ventricular function in clinical congestive heart failure
7. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
8. Plasma norepinephrine in congestive heart failure
9. Impaired chronotropic response to exercise in patients with congestive heart failure: Role of postsynaptic beta-adrenergic desensitization
10. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts
11. Assessment of the beta adrenergic receptor pathway in the intact failing human heart
12. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure
13. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
14. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double blind randomized, placebo-controlled trial
15. Increased beta receptor density and improved density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopatry
16. Long term beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy
17. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade
18. Long term beta-blockade in dilated cardiomyopathy: Effects of short and long term metoprolol treatment followed by withdrawal and readministration of metoprolol
19. Controlled trials with beta blockers in heart failure: Metoprolol as the prototype
20. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: Improvements in hemodynamic, contractile, and diastolic performance with bucindolol
21. Xamoterol in severe heart failure
22. Relationship between interleukin 1 (IL 1), tumor necrosis factor (TNF) and a neutrophil attracting peptide (NAP-1)
23. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines
24. cDNA cloning and characterization of interleukin 2-induced genes in a cloned T helper lymphocyte
25. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs
26. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
27. Assessment of the beta adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response
28. TNF-induced cardiomyopathy
29. Interleukin-1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B10.A mice
30. Therapeutic effect of anti-tumor necrosis factor alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus
31. Activation of Ca-permeable cation channels by myocarditis-associated antibody in guinea pig ventricular myocytes
32. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin induced myocarditis
33. Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial infarction
34. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure
35. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
36. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
37. Soluble interleukin-2 receptor in patients with dilated cardiomyopathy
38. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
39. Circulating cytokines and complements in chronic heart failure
40. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
41. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: Implications for clinical trials
42. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
43. Cytokines and endothelial cell biology
44. Tumor necrosis factor down-regulates an endothelial nitric oxide synthase mRNA by shortening its half-life
45. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells
46. Increased superoxide anion release from human endothelial cells in response to cytokines
47. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy
48. Diabetes and coronary artery disease
49. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function
50. Human coronary microvessels in diabetes and ischemia: Morphometric study of autopsy material
51. The myocardial microangiopathy in human and experimental diabetes mellitus: A microscopic, ultrastructural, morphomettic and computer-assisted symbolic-logic analysis
52. Effect of diabetes on metabolic coronary dilatation in the rat
53. Coronary dynamics and myocardial metabolism in the diabetic newborn lamb
54. Effects of hypoxia and adrenergic stimulation induced alterations in PGI2 synthesis by diabetic coronary arteries
55. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
56. A trial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor
57. Comparative vasoactive effects of native and synthetic atrial natriuretic factor (NAF)
58. Identification and plasma concentrations of the N-terminal fragment of atrial natriuretic factor in man
59. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure
60. HLA and hypertrophic cardiomyopathy
61. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies
62. Molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation
63. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy
64. Identification of mitochondrial proteins that serve as targets for autoimmunity in human dilated cardiomyopathy
65. Cardiac myosin and autoimmune myocarditis
66. Autoantibodies against betaadrenoreceptors in human idiopathic dilated cardiomyopathy
67. Antibodies to ADP-ATP carrier - An autoantigen in myocarditis and dilated cardiomyopathy - Impair cardiac function
68. Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo
69. Myocarditis and dilated cardiomyopathy: Clinical and experimental evidence implicating autoimmunity in tissue injury
70. Cardiotoxicity of anti tumor agents
71. Idiopathic cardiomyopathies. A review of pathologic studies and mechanisms of pathogenesis
72. Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy
73. Immunologic dialogue between cardiac myocytes, endothelial cells, and mononuclear cells
74. Deficient natural killer cell activity in patients with idiopathic cardiomyopathy
75. Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy
76. Reduced suppressor activity in congestive cardiomyopathy and in myocarditis
77. Beneficial effects of metoprolol treatment in congestive heart failure
78. Therapeutic effect of anti-tumor necrosis factor alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus
79. Efficacy and safety of monoclonal antibody to human tumor necrosis antibody to human necrosis factor alpha in patients with sepsis syndrome
80. Effect of gamma interferon on cachectin expression by mononuclear phagocytes: Reversal of the Ipsd (endotoxin resistance) phenotype
81. Cytokine generation capacities of monocytes are reduced in patients with severe heart failure
82. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
83. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery